A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
Janssen Research & Development, LLC
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- TERMINATED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2051
- sponsor
- Janssen Research & Development, LLC
- conditions
- Alzheimer's Disease
- interventions
- DRUG: Galantamine; DRUG: Placebo
- start date
- 2008-06-01
- primary completion date
- 2012-04-01
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT00679627
- Published
- May 19, 2008
- Updated
- Sep 19, 2013
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT00679627
- Categories
- Alzheimer's Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials